Icon Plc (NASDAQ:ICLR) – Jefferies Group increased their Q2 2018 earnings per share (EPS) estimates for Icon in a note issued to investors on Thursday, according to Zacks Investment Research. Jefferies Group analyst D. Windley now forecasts that the medical research company will post earnings per share of $1.48 for the quarter, up from their previous forecast of $1.47. Jefferies Group also issued estimates for Icon’s Q3 2018 earnings at $1.58 EPS, FY2018 earnings at $6.08 EPS and FY2019 earnings at $6.74 EPS.
ICLR has been the topic of a number of other research reports. BidaskClub upgraded Icon from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. KeyCorp restated a “buy” rating and issued a $130.00 price target on shares of Icon in a research note on Thursday, January 11th. Zacks Investment Research upgraded Icon from a “hold” rating to a “buy” rating and set a $127.00 price target on the stock in a research note on Wednesday, December 27th. ValuEngine raised Icon from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $133.00 price objective on shares of Icon in a report on Monday, January 22nd. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $126.00.
Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, February 15th. The medical research company reported $1.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.41 by $0.02. Icon had a return on equity of 27.55% and a net margin of 16.01%. The company had revenue of $455.10 million for the quarter, compared to analysts’ expectations of $455.66 million. During the same quarter in the prior year, the business posted $1.33 EPS. The business’s revenue was up 4.6% compared to the same quarter last year.
A number of hedge funds and other institutional investors have recently modified their holdings of ICLR. Schwab Charles Investment Management Inc. grew its holdings in Icon by 39.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 16,713 shares of the medical research company’s stock valued at $1,635,000 after buying an additional 4,692 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Icon by 5.5% during the 2nd quarter. Northern Trust Corp now owns 249,247 shares of the medical research company’s stock worth $24,373,000 after purchasing an additional 13,099 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Icon by 19.8% during the 2nd quarter. Vanguard Group Inc. now owns 14,545 shares of the medical research company’s stock worth $1,422,000 after purchasing an additional 2,400 shares in the last quarter. Gotham Asset Management LLC acquired a new stake in shares of Icon during the 2nd quarter worth $392,000. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of Icon by 11.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,844 shares of the medical research company’s stock worth $474,000 after purchasing an additional 481 shares in the last quarter. 90.50% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Q2 2018 EPS Estimates for Icon Plc (ICLR) Increased by Analyst” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://stocknewstimes.com/2018/03/14/jefferies-group-weighs-in-on-icon-plcs-q2-2018-earnings-iclr.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.